NCT05218889 2024-12-31Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerChinese PLA General HospitalPhase 1/2 Recruiting90 enrolled
NCT05832892 2024-06-14Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerShanghai Zhongshan HospitalPhase 1/2 Unknown41 enrolled